ADAR1 Capital Management »

Aslan Pharmaceuticals shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Aslan Pharmaceuticals (ASLN) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Aslan Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Aslan Pharmaceuticals held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aslan Pharmaceuticals by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $37k 59k 0.62

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Aslan Pharmaceuticals

Shay Capital
Sio Capital Management
Two Sigma Securities
Morgan Stanley
Qube Research & Technologies

View all funds holding Aslan Pharmaceuticals